Promotion of antiinflammatory effects via pharmacological activation of the orphan nuclear hormone receptors may be advantageous in the treatment of CAD and other cardiometabolic disorders and will be the focus of future studies. This evidence concerns the gene NR1I3 and coronary artery disorder.